Literature DB >> 14669797

Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase.

Daotai Nie1, Jeffrey Nemeth, Yan Qiao, Alex Zacharek, Li Li, Kenny Hanna, Keqin Tang, Gilda G Hillman, Michael L Cher, David J Grignon, Kenneth V Honn.   

Abstract

Arachidonate 12-lipoxygenase (LOX) converts arachidonic acid to 12(S)-hydroxyeicosatetraenoic acid (HETE), a bioactive lipid implicated in tumor angiogenesis, growth, and metastasis. Alteration in 12-LOX expression or activity has been reported in various carcinomas including prostate carcinoma. However, little is known about the impact of the altered expression or activity of 12-LOX on tumor metastasis. In the present study, we examined whether or not an increase in 12-LOX expression in human prostate carcinoma cells can modulate their metastatic potential. We report that increased expression of 12-LOX in PC-3 cells caused a significant change in cell adhesiveness, spreading, motility, and invasiveness. Specifically 12-LOX transfected PC-3 cells were more adhesive toward vitronectin, type I and IV collagen, but not to fibronectin or laminin, than cells transfected with control vector. Increased spreading on vitronectin, fibronectin, collagen type I and IV also was observed in 12-LOX transfected PC-3 cells when compared to control PC-3 cells. The increased spreading of 12-LOX transfected PC-3 cells was blocked by treatment with 12-LOX inhibitors, baicalein and CDC. 12-LOX transfected PC-3 cells were more invasive through Matrigel than cells transfected with control vector. In vivo, tumor cell invasion to surrounding muscle or fat tissues was more frequent in nude mice bearing s.c. tumors from 12-LOX transfected PC-3 cells than in those from control vector transfected cells. When injected via the tail vein into SCID mice with implanted human bone fragments, there was an increase in tumor metastasis to human bone by 12-LOX transfected PC-3 cells in comparison to control vector transfected cells. Taken together, our data suggest that an increase in 12-LOX expression enhances the metastatic potential of human prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14669797     DOI: 10.1023/a:1027302408187

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  25 in total

1.  A lipoxygenase metabolite, 12-(S)-HETE, stimulates protein kinase C-mediated release of cathepsin B from malignant cells.

Authors:  K V Honn; J Timár; J Rozhin; R Bazaz; M Sameni; G Ziegler; B F Sloane
Journal:  Exp Cell Res       Date:  1994-09       Impact factor: 3.905

2.  Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer.

Authors:  L E Heasley; S Thaler; M Nicks; B Price; K Skorecki; R A Nemenoff
Journal:  J Biol Chem       Date:  1997-06-06       Impact factor: 5.157

3.  Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.

Authors:  S H Hong; I Avis; M D Vos; A Martínez; A M Treston; J L Mulshine
Journal:  Cancer Res       Date:  1999-05-01       Impact factor: 12.701

4.  Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells.

Authors:  X Z Ding; P Iversen; M W Cluck; J A Knezetic; T E Adrian
Journal:  Biochem Biophys Res Commun       Date:  1999-07-22       Impact factor: 3.575

5.  Lipoxygenase metabolites of arachidonic and linoleic acids modulate the adhesion of tumor cells to endothelium via regulation of protein kinase C.

Authors:  B Liu; J Timar; J Howlett; C A Diglio; K V Honn
Journal:  Cell Regul       Date:  1991-12

6.  Regulation of melanoma-cell motility by the lipoxygenase metabolite 12-(S)-HETE.

Authors:  J Timar; S Silletti; R Bazaz; A Raz; K V Honn
Journal:  Int J Cancer       Date:  1993-12-02       Impact factor: 7.396

7.  12(S)-hydroxyeicosatetraenoic acid increases the actin microfilament content in B16a melanoma cells: a protein kinase-dependent process.

Authors:  R L Rice; D G Tang; M Haddad; K V Honn; J D Taylor
Journal:  Int J Cancer       Date:  1998-07-17       Impact factor: 7.396

8.  Biosynthesis of 12(S)-hydroxyeicosatetraenoic acid by B16 amelanotic melanoma cells is a determinant of their metastatic potential.

Authors:  B Liu; L J Marnett; A Chaudhary; C Ji; I A Blair; C R Johnson; C A Diglio; K V Honn
Journal:  Lab Invest       Date:  1994-03       Impact factor: 5.662

9.  12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha.

Authors:  B Liu; R J Maher; Y A Hannun; A T Porter; K V Honn
Journal:  J Natl Cancer Inst       Date:  1994-08-03       Impact factor: 13.506

10.  Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer.

Authors:  X Gao; D J Grignon; T Chbihi; A Zacharek; Y Q Chen; W Sakr; A T Porter; J D Crissman; J E Pontes; I J Powell
Journal:  Urology       Date:  1995-08       Impact factor: 2.649

View more
  23 in total

1.  Roles of Eicosanoids in Prostate Cancer.

Authors:  Kasem Nithipatikom; William B Campbell
Journal:  Future Lipidol       Date:  2008-08-01

2.  Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2.

Authors:  Naoko Kobayashi; R James Barnard; Susanne M Henning; David Elashoff; Srinivasa T Reddy; Pinchas Cohen; Pak Leung; Jenny Hong-Gonzalez; Stephen J Freedland; Jonathan Said; Dorina Gui; Navindra P Seeram; Laura M Popoviciu; Dilprit Bagga; David Heber; John A Glaspy; William J Aronson
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

Review 3.  Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis.

Authors:  Manoj Kumar; Sunil Kumar Dhatwalia; D K Dhawan
Journal:  Tumour Biol       Date:  2016-09-10

Review 4.  The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.

Authors:  Prasanna Ekambaram; Wanyu Lambiv; Rosanna Cazzolli; Anthony W Ashton; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

5.  12-HETER1/GPR31, a high-affinity 12(S)-hydroxyeicosatetraenoic acid receptor, is significantly up-regulated in prostate cancer and plays a critical role in prostate cancer progression.

Authors:  Kenneth V Honn; Yande Guo; Yinlong Cai; Menq-Jer Lee; Gregory Dyson; Wenliang Zhang; Stephanie C Tucker
Journal:  FASEB J       Date:  2016-03-10       Impact factor: 5.191

Review 6.  Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid.

Authors:  William S Powell; Joshua Rokach
Journal:  Biochim Biophys Acta       Date:  2014-10-29

7.  Expression and function of fatty acid amide hydrolase in prostate cancer.

Authors:  Michael P Endsley; Rebecca Thill; Iffat Choudhry; Carol L Williams; Andre Kajdacsy-Balla; William B Campbell; Kasem Nithipatikom
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

8.  Multifactorial anticancer effects of digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and inhibition of lymphendothelial gap formation in vitro.

Authors:  S Madlener; P Saiko; C Vonach; K Viola; N Huttary; N Stark; R Popescu; M Gridling; N T-P Vo; I Herbacek; A Davidovits; B Giessrigl; S Venkateswarlu; S Geleff; W Jäger; M Grusch; D Kerjaschki; W Mikulits; T Golakoti; M Fritzer-Szekeres; T Szekeres; G Krupitza
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

9.  Association between polymorphisms of arachidonate 12-lipoxygenase (ALOX12) and schizophrenia in a Korean population.

Authors:  Tae Kim; Hak-Jae Kim; Jin Kyung Park; Jong Woo Kim; Joo-Ho Chung
Journal:  Behav Brain Funct       Date:  2010-07-14       Impact factor: 3.759

Review 10.  Mammalian lipoxygenases and their biological relevance.

Authors:  Hartmut Kuhn; Swathi Banthiya; Klaus van Leyen
Journal:  Biochim Biophys Acta       Date:  2014-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.